latest news releases from the newsroom
Basilea Pharmaceutica Ltd
Basilea Announces Positive Top-Line Results On Second Pivotal Phase III Ceftobiprole Trial
BASEL, Switzerland, Jan. 10, 2007 (PRIME NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SWX:BSLN) announced today that the second pivotal ceftobiprole phase III study in complicated skin infections met its primary endpoint of statistical non-inferiority versus combination therapy. Ceftobiprole demonstrated high cure rates in patients with complicated Gram-positive as well as Gram-negative skin infections, including diabetic patients with foot infections. A first regulatory submission is planned this year. Ceftobiprole is an anti-MRSA, broad-spectrum cephalosporin developed in collaboration with Cilag GmbH International, a Johnson & Johnson company.
First Solar, Inc.
First Solar Increases Volumes Under Long-Term Sales Contracts
PHOENIX, Jan. 9, 2007 (PRIME NEWSWIRE) -- First Solar, Inc. (Nasdaq:FSLR) today announced that the Company has amended four of its existing long-term supply contracts to increase the total volume of modules to be sold between 2009 and 2012 by an aggregate of 264MW. "The additional volumes under the long-term supply contracts enable our customers to better plan and build their businesses and advance our goal of securing long-term revenue visibility," stated Michael J. Ahearn, Chief Executive Officer of the Company. "We continue to see solid demand and price elasticity as a low cost manufacturer in the industry."